Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials

BACKGROUND: Vandetanib is a promising anticancer target agent for treating advanced carcinomas, such as non-small-cell lung cancer (NSCLC) and breast cancer. Rash is a frequently reported adverse event of vandetanib. We conducted this meta-analysis to determine the incidence rate and overall risks o...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuan, Qi, Manli, Hou, Shuping, Shao, Lili, Zhang, Junyan, Li, Yan, Liu, Quanzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671843/
https://www.ncbi.nlm.nih.gov/pubmed/29069010
http://dx.doi.org/10.1097/MD.0000000000008345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671843/
https://www.ncbi.nlm.nih.gov/pubmed/29069010
http://dx.doi.org/10.1097/MD.0000000000008345

Ejemplares similares